Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement

NCT ID: NCT02288663

Last Updated: 2021-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-03

Study Completion Date

2022-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glomerular filtration rate (GFR) is the recommended parameter to assess renal function. The reference technique to measure GFR (clearance of a glomerular agent) is not commonly used. Instead, estimations (eGFR) are routinely taken from serum creatinine (SCr) with several published formulae: Cockcroft and Gault, MDRD, CKD-EPI. Basically, all these formulae aim at predicting the endogenous creatinine production by morphological parameters (age, body weight...) However, in the elderly, muscular mass is extremely variable and sarcopenia is quite commonly encountered (frequently linked to Alzheimer disease). This is probably the main reason why the aforementioned formulae are not valid in this population: for a given renal function, a lower muscular mass induces a lower creatinine production and, henceforth, a lower SCr value, which gives an overestimation of eGFR.

Muscular mass is closely linked to lean body mass (LBM), which can be properly assessed by whole-body dual X-ray absorptiometry (DXA). Alternatively, Bioelectric Impedance Spectroscopy (BIS) can also be used.

Investigators postulate that it is possible to estimate GFR in the elderly from both SCr and LBM estimation from DXA. Proof of concept has already been made by others but until now, no specific formula for the elderly has been devised and properly validated.

Investigators'aim is thus to propose a new formula to predict GFR from both SCr and LBM (estimated from DXA) in the elderly. This formula will be elaborated from a first series of 100 patients and validated on a second series of 100 other patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Freage group

only one group in this trial. All the participants will follow all the listed interventions.

Group Type OTHER

measurement of morphological parameters

Intervention Type OTHER

measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.

a blood sample

Intervention Type BIOLOGICAL

One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.

albumin or blood in urine

Intervention Type BIOLOGICAL

dipstick analysis for albumin or blood in urine

Dual X-ray absorptiometry (DXA)

Intervention Type DEVICE

measurement of lean body mass by whole-body DXA

Bioelectric Impedance Spectroscopy (BIS)

Intervention Type DEVICE

measurement of lean body mass by BIS

51Cr-EDTA plasma clearance

Intervention Type BIOLOGICAL

measurement of 51Cr-EDTA plasma clearance to determine GFR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measurement of morphological parameters

measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.

Intervention Type OTHER

a blood sample

One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.

Intervention Type BIOLOGICAL

albumin or blood in urine

dipstick analysis for albumin or blood in urine

Intervention Type BIOLOGICAL

Dual X-ray absorptiometry (DXA)

measurement of lean body mass by whole-body DXA

Intervention Type DEVICE

Bioelectric Impedance Spectroscopy (BIS)

measurement of lean body mass by BIS

Intervention Type DEVICE

51Cr-EDTA plasma clearance

measurement of 51Cr-EDTA plasma clearance to determine GFR

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age of 75 years of more
* origin from Western Europe or North Africa
* covered by social health insurance
* general health condition allowing transportation and ambulatory procedures during one day

Exclusion Criteria

* ascitis, oedema or third compartment
* fast change in body weight (more than 5% in less than one week)
* eGFR \< 30 mL/min/1.73 m² (using MDRD formula)
* legal concerns: prisoners, guardianship, lack of health insurance, failure to consent
* intake of drugs that interfere with creatinine tubular secretion

* cimetidine
* trimethoprim
* intake of drugs that interfere with creatinine assay

* calcium dobesilate
* hydroxocobalamin
* N-ethylglycine
* phenindione
* lidocaine
* inability to lie during 10 minutes without moving
* patients who are bedridden, hemiplegic or highly dependent on others
* any health condition that, in the investigator's opinion, could rapidly (\< 1 week) vary the extracellular volume or GFR (these is voluntarily left open to the investigator because it is hardly possible to make an exhaustive list here)
Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emmanuel DURAND, Professor

Role: CONTACT

3 69 55 04 58 ext. 0033

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fabrice HUBELE, MD

Role: primary

3 88 12 75 47 ext. 0033

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5744

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.